It also reports on financial highlights. InterAx Biotech AG, a pharmaceutical development company pioneering computational pharmacology for drug discovery, announces the award of a prestigious, highly competitive grant to apply its drug discovery and development platform to Commission-sponsored innovative technologies programmes. European
The total volume of the Horizon Europe EIC Pathfinder project is 3.7 million euros, which is distributed among the project participants. In this consortium, InterAx has raised more than 700k. The goals of the consortium are to implement innovative methods to characterize the intracellular functions of drug candidates, a critical component in the lead compound selection process. A key goal is to generate high-quality data sets to train AI algorithms to elucidate biological responses. Each participant brings a unique and complementary set of knowledge and technologies to the program. InterAx was selected following review by a group of experts, who recognized the pioneering use of mathematical models and AI in the development of drugs with specific cellular effects as crucial to the success of the program. Dr. Aurélien Rizk, Scientific Director, stated : “The reviewers have recognized our development of a cutting-edge computer-assisted drug discovery platform. It excels at decoding intricate intracellular biological responses, identifying ideal cellular effects that maximize efficacy while minimizing side effects, and designing of new drugs accordingly.” Dr Chris Prior, CEO, said: “We are delighted to have been selected for a highly competitive European grant which has a historical success rate of around 4%. This is a tremendous validation of peer review that honors InterAx’s multidisciplinary team of scientists, experts in organic and computational chemistry, biophysics, molecular biology, pharmacology, mathematics and artificial intelligence. Dr Prior added: “This award greatly complements our funding needs, as well as adding significant validation in support of fundraising efforts and conversations with partners. We are also very pleased with the strong support from our investors in a recent financing. The raising will advance our two main internal programs in cancer and inflammation towards IND and this will prepare us for the next phase of financing.”InterAx Biotech AG The company, a spin-out of the ETH Zurich and the Paul Scherrer Institute in Switzerland has developed an integrated drug discovery process that combines biochemical screening of compounds, mathematical modeling of cellular pathways and chemical structure-function relationship based on Artificial Intelligence. This unique approach enables rapid and accurate identification of novel cellular mechanisms to develop differentiated products that stand out for their efficacy and safety profiles. This platform unlocks previously untreatable targets, shortens drug discovery timelines from years to months, and reduces risk. The company specializes in drug discovery for G protein-coupled receptors (GPCRs) and is involved in the generation and optimization of targets, including orphan GPCRs. InterAx has a team of highly experienced scientists specialized in AI, mathematical modeling of signaling pathways, cellular pharmacology and computational chemistry. The company is currently funded by institutional investors and a grant from the European Commission, and is preparing for the next round of financing to expand its capabilities and advance the development of drug candidates.More information: linkedin. com/company/interax-biotech www.interaxbiotech.com
ContactContact name: Luca ZenoneContact description: InterAx Biotech AGContact phone: 41 56 310 5754
